Based on the preliminary investigations which are summarized in the body of their application, they have demonstrated that significant levels of CSF-1Rs (the fms-protooncogene product) are expressed by neoplastic mammary epithelial cells in vivo and in vitro; and that activation of this receptor on breast carcinoma cells by its cognate ligand, the macrophage-colony stimulating factor, CSF-1 increases the expression & cell surface localization of specific proteases and stimulates the invasion of basement membrane analogues such as human amnionic membrane and Matrigel. They have also demonstrated in vitro that levels of expression of this receptor are greatly augmented by glucocorticoids in some breast carcinoma-derived cultured cell lines, but not in others. Based on these observations, they have hypothesized that transcription and level of expression of CSF-1R is increased in (benign and neoplastic) mammary epithelial cells by glucocorticoids and down regulated by antagonists such as RU-486 in vivo and in vitro. They have also hypothesized that the regulation of transcription of the first CSF-1R promoter by glucocorticoids in breast carcinoma cells is further modulated by one or more accessory transcription factors which explain why this promoter is responsive to glucocorticoids in some cell lines and whose action in vivo to render the CSF-1R promoter responsive (or refractory) to glucocorticoids--ubiquitous and omnipresent steroid hormones--may help explain the variance in levels of CSF-1R expression observed in vivo in breast carcinoma specimens. They propose to test these hypotheses by continuing the investigations of steroid hormone regulation of CSF-1R gene expression--specifically focusing on the more complete characterization of those elements of the first CSF-1R promoter (and the proteins which bind to them) responsible for the observed stimulation of CSF-1R gene transcription in BT20 and SKBR3 but not MCF-7 breast carcinoma cell lines and determining whether the levels of expression of these """"""""accessory"""""""" factors correlates with the level of expression of CSF-1R observed in human breast carcinoma tissue specimens. They also propose to determine whether glucocorticoids and their antagonists modulate the expression of CSF-1R in human breast carcinoma specimens maintained ex vivo in short-term organ culture and in vivo in nude mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA074832-01A1
Application #
2630742
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mohla, Suresh
Project Start
1998-07-01
Project End
2001-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kluger, Harriet M; Kluger, Yuval; Gilmore-Hebert, Maureen et al. (2004) cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 84:320-31
Kluger, Harriet M; Dolled-Filhart, Marisa; Rodov, Sofya et al. (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10:173-7
Toy, E P; Chambers, J T; Kacinski, B M et al. (2001) The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 80:194-200
Han, S C; Kim, D H; Higgins, S A et al. (2000) Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 47:1235-44
Sapi, E; Kacinski, B M (1999) The role of CSF-1 in normal and neoplastic breast physiology. Proc Soc Exp Biol Med 220:1-8
Kacinski, B M; Rodov, S; Sapi, E (1999) Signal transduction pathways regulated by CSF-1 receptors modulate the in vitro radiosensitivity of mammary epithelial cells. Int J Radiat Oncol Biol Phys 45:969-73